Early expression changes of complement regulatory proteins and C5a receptor (CD88) on leukocytes after multiple injury in humans

Shock

Volumn 33, Issue 6, 2010, Pages 568-575

  Amara, Umme ^a   Kalbitz, Miriam ^a   Perl, Mario ^a   Flierl, Michael A ^b   Rittirsch, Daniel ^a   Weiss, Manfred ^a   Schneider, Marion ^a   Gebhard, Florian ^a   Huber Lang, Markus ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

C5aR; CD35; CD46; CD55; CD59; Complement; Polytrauma

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT REGULATORY PROTEIN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL TYPE; CLINICAL ARTICLE; COMPLEMENT DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EMERGENCY WARD; FEMALE; FLOW CYTOMETRY; HOSPITAL ADMISSION; HUMAN; INJURY SEVERITY; LEUKOCYTE; LYMPHOCYTE; MALE; MONOCYTE; MULTIPLE TRAUMA; NEUTROPHIL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE TRAUMA; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B;

EID: 77952329423     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181c799d4     Document Type: Article

References (35)

1. Bianchi ME, Manfredi AA: Immunology. Dangers in and out. Science 323:1683-1684, 2009.
2. Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, Kohl J: Circulating complement proteins in multiple trauma patientsVcorrelation with injury severity, development of sepsis, and outcome. Crit Care Med 25:2015-2024, 1997.
3. Ganter MT, Brohi K, Cohen MJ, Shaffer LA, Walsh MC, Stahl GL, Pittet JF: Role of the alternative pathway in the early complement activation following major trauma. Shock 28:29-34, 2007.
4. Ward PA: The dark side of C5a in sepsis. Nat Rev Immunol 4:133-142, 2004.
5. Keel M, Trentz O: Pathophysiology of polytrauma. Injury 36:691-709, 2005.
6. Smith BO, Mallin RL, Krych-Goldberg M, Wang X, Hauhart RE, Bromek K, Uhrin D, Atkinson JP, Barlow PN: Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 108:769-780, 2002.
7. Bjorge L, Jensen TS, Matre R: Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 42:185-192, 1996.
8. Makidono C, Mizuno M, Nasu J, Hiraoka S, Okada H, Yamamoto K, Fujita T, Shiratori Y: Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis. J Lab Clin Med 143:152-158, 2004.
9. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS: Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759-1766, 2008.
10. Koretz K, Bruderlein S, Henne C, Moller P: Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 68:926-931, 1993.
11. Marcenaro E, Augugliaro R, Falco M, Castriconi R, Parolini S, Sivori S, Romeo E, Millo R, Moretta L, Bottino C, et al.: CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. Eur J Immunol 33:3367-3376, 2003.
12. Flierl MA, Perl M, Rittirsch D, Bartl C, Schreiber H, Fleig V, Schlaf G, Liener U, Brueckner UB, Gebhard F, et al.: The role of C5a in the innate immune response after experimental blunt chest trauma. Shock 29:25-31, 2008.
13. Xu DZ, Zaets SB, Chen R, Lu Q, Rajan H, Yang X, Zhang J, Feketova E, Bogdan N, Deitch EA, et al.: Elimination of C5aR prevents intestinal mucosal damage and attenuates neutrophil infiltration in local and remote organs. Shock 31:493-499, 2009.
14. World Health Organization: World report on road traffic injury prevention. Available at: http://www.who.int/violence-injury-prevention/ publications/road-traffic/world-report/en/index.html. Accessed April 1, 2009.
15. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, et al.: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12: 682-687, 2006.
16. Weeks C, Moratz C, Zacharia A, Stracener C, Egan R, Peckham R, Moore FD Jr, Tsokos GC: Decay-accelerating factor attenuates remote ischemia-reperfusionY initiated organ damage. Clin Immunol 124:311-327, 2007.
17. Ayala A, Perrin MM, Meldrum DR, Ertel W, Chaudry IH: Hemorrhage induces an increase in serum TNF which is not associated with elevated levels of endotoxin. Cytokine 2:170-174, 1990.
18. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
19. Lidington EA, Haskard DO, Mason JC: Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase CYdependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 96:2784-2792, 2000.
20. Yamada K, Miwa T, Liu J, Nangaku M, Song WC: Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 172: 3869-3875, 2004.
21. Pedersen ED, Aass HC, Rootwelt T, Fung M, Lambris JD, Mollnes TE: CD59 efficiently protects human NT2-N neurons against complement-mediated damage. Scand J Immunol 66:345-351, 2007.
22. Stahel PF, Flierl MA, Morgan BP, Persigehl I, Stoll C, Conrad C, Touban BM, Smith WR, Beauchamp K, Schmidt OI, et al.: Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. J Neuroinflammation 6:2, 2009.
23. Iida K, Nussenzweig V: Complement receptor is an inhibitor of the complement cascade. J Exp Med 153:1138-1150, 1981.
24. Arora V, Verma J, Dutta R, Marwah V, Kumar A, Das N: Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythema-tosus. Mol Immunol 41:449-456, 2004.
25. Pascual M, Duchosal MA, Steiger G, Giostra E, Pechere A, Paccaud JP, Danielsson C, Schifferli JA: Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol 151:1702-1711, 1993.
26. Mollnes TE, Kirschfink M: Strategies of therapeutic complement inhibition. Mol Immunol 43:107-121, 2006.
27. Morgan BP, Rushmere NK, Harris CL: Therapeutic uses of recombinant complement receptors. Biochem Soc Trans 26:49-54, 1998.
28. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146-151, 1990.
29. Cattaneo R: Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol 78:4385-4388, 2004.
30. Liszewski MK, Kemper C, Price JD, Atkinson JP: Emerging roles and new functions of CD46. Springer Semin Immunopathol 27:345-358, 2005.
31. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P: CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 280:36342-36354, 2005.
32. Endoh M, Yamashina M, Ohi H, Funahashi K, Ikuno T, Yasugi T, Atkinson JP, Okada H: Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 94:182-188, 1993.
33. Kroshus TJ, Salerno CT, Yeh CG, Higgins PJ, Bolman RM III, Dalmasso AP: A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation 69:2282-2289, 2000.
34. Furebring M, Hakansson LD, Venge P, Nilsson B, Sjolin J: Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 6:363-370, 2002.
35. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, Younkin EM, Kunkel RG, Ding J, Erickson R, et al.: Role of C5a in multi-organ failure during sepsis. J Immunol 166:1193-1199, 2001.